Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.

Sheth NP, Sheth NP, Smith JR, Winzenrieth R, Humbert L, Wang Y, Boxberger JI, Bostrom MP

The Journal of bone and joint surgery. American volume1 May 2024Cited by 9 (Europe PMC)

PMID38691582PMCIDPMC11594069DOI10.2106/jbjs.23.01334PepBankPUB-38691582

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, abaloparatide increased integral volumetric BMD more than placebo in all assessed Gruen zones at months 6 and 18.
In plain wordsIn women with osteoporosis, abaloparatide increased integral bone density more than placebo in all assessed zones.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseIntegral volumetric BMD
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Compared with placebo, the abaloparatide group showed greater increases in integral volumetric BMD in all zones at months 6 and 18
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158201
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased cortical surface BMD more than placebo in zones 1, 6, and 7 at month 6.
In plain wordsIn women with osteoporosis, abaloparatide increased cortical surface bone density more than placebo in the specified zones at month 6.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical surface BMD at month 6
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
cortical surface BMD in zones 1, 6, and 7 at month 6
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158202
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased cortical thickness more than placebo in all assessed zones at month 18.
In plain wordsIn women with osteoporosis, abaloparatide increased cortical thickness more than placebo at month 18.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical thickness at month 18
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
cortical thickness, cortical volumetric BMD, and cortical surface BMD in all zones at month 18
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158203
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased cortical volumetric BMD more than placebo in all assessed zones at month 18.
In plain wordsIn women with osteoporosis, abaloparatide increased cortical bone density more than placebo at month 18.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical volumetric BMD at month 18
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
cortical thickness, cortical volumetric BMD, and cortical surface BMD in all zones at month 18
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158204
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased cortical surface BMD more than placebo in all assessed zones at month 18.
In plain wordsIn women with osteoporosis, abaloparatide increased cortical surface bone density more than placebo at month 18.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical surface BMD at month 18
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
cortical thickness, cortical volumetric BMD, and cortical surface BMD in all zones at month 18
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158205
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, abaloparatide increased trabecular volumetric BMD more than placebo in zones 1 and 7 at months 6 and 18.
In plain wordsIn women with osteoporosis, abaloparatide increased trabecular bone density more than placebo in the specified zones.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular volumetric BMD
Study
n = 500
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
and trabecular volumetric BMD in zones 1 and 7 at months 6 and 18.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis obtained dual x-ray absorptiometry (DXA) hip scans from 500 randomly selected postmenopausal women with osteoporosis from the Phase-3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE, NCT01343004) study after 0, 6, and 18 months of abaloparatide (250 patients) or…
Report a problemFND-3869158206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.